{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:28:20Z","timestamp":1781036900367,"version":"3.54.1"},"reference-count":36,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Assess pooled safety results through the end of the phase II\/III studies of guselkumab (GUS; \u2264 2 years) in tumor necrosis factor inhibitor (TNFi)-na\u00efve and -experienced patients with psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were pooled from the Phase 2 and DISCOVER-1 (both TNFi-na\u00efve and -experienced), DISCOVER-2 (TNFi-na\u00efve), and COSMOS (TNFi-experienced) studies. Patients with active PsA were randomized to GUS 100 mg every 4 or 8 weeks (Q4W + Q8W = Combined GUS) or placebo (PBO) with crossover to GUS Q4W or Q8W at week 24. Time-adjusted adverse event (AE) rates (events\/100 patient-years [PY]) and clinical laboratory findings were assessed during the PBO-controlled period and through end of study (\u2264 2 years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1554 randomized patients (n = 373 [GUS Q4W], 664 [GUS Q8W], and 517 [PBO]), 1138 (73.23%) were TNFi-na\u00efve and 416 (26.77%) were TNFi-experienced. Respective AE rates through week 24 were 220.8\/100 PY (TNFi-na\u00efve) and 251.6\/100 PY (TNFi-experienced) in the Combined GUS group and 196.1\/100 PY (TNFi-na\u00efve) and 303.0\/100 PY (TNFi-experienced) in the PBO group. Among all GUS-treated patients (including those who crossed over from PBO), low AE rates were maintained during long-term evaluation in both TNFi-na\u00efve (139.7\/100 PY) and TNFi-experienced (174.0\/100 PY) patients. Rates\/100 PY of AEs leading to treatment discontinuation, serious AEs, and other AEs of interest, as well as occurrence of elevated hepatic transaminase levels and decreased neutrophil counts were consistent between PBO and GUS-treated patients through week 24 regardless of prior TNFi use and remained low through the end of the studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The safety profile of GUS in TNFi-experienced patients was consistent with that in TNFi-na\u00efve patients, which remained favorable for up to 2 years. [<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>: Phase 2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02319759\">NCT02319759<\/jats:ext-link>), DISCOVER-1 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03162796\">NCT03162796<\/jats:ext-link>), DISCOVER-2 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03158285\">NCT03158285<\/jats:ext-link>), and COSMOS (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03796858\">NCT03796858<\/jats:ext-link>)]<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220928","type":"journal-article","created":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T13:25:12Z","timestamp":1673789112000},"page":"769-780","source":"Crossref","is-referenced-by-count":16,"title":["Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2029","authenticated-orcid":false,"given":"Proton","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-7124","authenticated-orcid":false,"given":"Wolf-Henning","family":"Boehncke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8618","authenticated-orcid":false,"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3435-8118","authenticated-orcid":false,"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Theander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marilise","family":"Marrache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-1780","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,1,15]]},"reference":[{"key":"2023060503351751000_50.6.769.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"2023060503351751000_50.6.769.2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nature Rev Rheumatol"},{"key":"2023060503351751000_50.6.769.3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000596"},{"key":"2023060503351751000_50.6.769.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"2023060503351751000_50.6.769.5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3593-x"},{"key":"2023060503351751000_50.6.769.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"2023060503351751000_50.6.769.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.001"},{"key":"2023060503351751000_50.6.769.8","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0215-7"},{"key":"2023060503351751000_50.6.769.9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000880"},{"key":"2023060503351751000_50.6.769.10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/08923973.2011.653646","article-title":"Safety of anti-TNF\u03b1 agents in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Girolomoni","year":"2012","journal-title":"Immunopharm Immunoto"},{"key":"2023060503351751000_50.6.769.11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"key":"2023060503351751000_50.6.769.12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.clinthera.2019.04.030","article-title":"Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis","volume":"41","author":"Costello","year":"2019","journal-title":"Clin Ther"},{"key":"2023060503351751000_50.6.769.13","unstructured":"COSENTYX [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp.; 2021."},{"key":"2023060503351751000_50.6.769.14","unstructured":"HUMIRA [package insert]. Chicago, IL: AbbVie Inc.; 2021."},{"key":"2023060503351751000_50.6.769.15","unstructured":"SILIQ [package insert]. Bridgewater, NJ: Bausch Health US, LLC; 2020."},{"key":"2023060503351751000_50.6.769.16","unstructured":"SKYRIZI [package insert]. Chicago, IL: AbbVie Inc.; 2022."},{"key":"2023060503351751000_50.6.769.17","unstructured":"STELARA [package insert]. Horsham, PA: Janssen Biotech, LLC; 2020."},{"key":"2023060503351751000_50.6.769.18","unstructured":"TALTZ [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022."},{"key":"2023060503351751000_50.6.769.19","unstructured":"TREMFYA [package insert]. Horsham, PA: Janssen Biotech, LLC; 2020."},{"key":"2023060503351751000_50.6.769.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"2023060503351751000_50.6.769.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2023060503351751000_50.6.769.22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457"},{"key":"2023060503351751000_50.6.769.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2023060503351751000_50.6.769.24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.41553","article-title":"Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-na\u00efve patients with psoriatic arthritis","volume":"73","author":"McInnes","year":"2021","journal-title":"Arthritis Rheum"},{"key":"2023060503351751000_50.6.769.25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through 2 years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-na\u00efve patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2023060503351751000_50.6.769.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"2023060503351751000_50.6.769.27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"2023060503351751000_50.6.769.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201532"},{"key":"2023060503351751000_50.6.769.29","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/ijms21197041","article-title":"The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic","volume":"21","author":"Woo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2023060503351751000_50.6.769.30","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2023060503351751000_50.6.769.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.2186"},{"key":"2023060503351751000_50.6.769.32","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"2023060503351751000_50.6.769.33","doi-asserted-by":"crossref","first-page":"i025","DOI":"10.1093\/ecco-jcc\/jjab232.022","article-title":"The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: Phase 2b QUASAR Study results through week 12 (ECCO Abstract OP23)","volume":"16","author":"Dignass","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2023060503351751000_50.6.769.34","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","article-title":"Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023060503351751000_50.6.769.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.556"},{"key":"2023060503351751000_50.6.769.36","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T10:37:32Z","timestamp":1685961452000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,15]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.3899\/jrheum.220928"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220928","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,15]]}}}